Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease
Status:
RECRUITING
Trial end date:
2032-12-31
Target enrollment:
Participant gender:
Summary
In this double-blind phase II randomized controlled trial, patients with lung cancer or ≤2 oligometastatic pulmonary lesions and a concomitant diagnosis of ILD who are planned for radical Radiation Therapy (RT) will be randomized using a 2 x 2 factorial design to oral N-acetylcysteine (NAC) versus placebo, and also to short course corticosteroids versus placebo.
Phase:
PHASE2
Details
Lead Sponsor:
David Palma
Collaborators:
Centre Hospitalier de l'Universite de Montreal (CHUM) London Health Sciences Centre